SCHEMBL26608432

SCHEMBL26608432

Nc1c(OCc2ccccc2)cc(Cl)nc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 1/20 0.46
▸ LTA4H P09960 1/20 0.45
▸ MAPK14 Q16539 1/20 0.45
▸ HTT P42858 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ STAT3 P40763 1/20 0.44
▸ MGAM O43451 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ SI P14410 1/20 0.42
▸ MGAM2 Q2M2H8 1/20 0.42
▸ PLAU P00749 1/20 0.42
▸ DCPS Q96C86 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ FOLH1 Q04609 1/20 0.40
▸ MAOB P27338 2/20 0.40
▸ TSHR P16473 1/20 0.39
▸ ATP4A P20648 1/20 0.39
▸ ATP4B P51164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601702 0.82 HTT (0.51) MPOLTA4HMAPK14HTTSMN1; SMN2
SCHEMBL22850860 0.78 MAPT (0.43) MPOLTA4HMAPK14HTTSMN1; SMN2
SCHEMBL26601848 0.77 HTT (0.51) MAPK14HTTSMN1; SMN2STAT3LMNA
SCHEMBL4282091 0.74 AGPAT2 (0.53) —
SCHEMBL31394965 0.74 SMN1; SMN2 (0.50) MPOLTA4HMAPK14HTTSMN1; SMN2
SCHEMBL26607243 0.74 SMN1; SMN2 (0.51) HTTSMN1; SMN2STAT3DCPSLMNA
SCHEMBL16094138 0.74 PLAU (0.45) LTA4HMAPK14HTTSMN1; SMN2STAT3
SCHEMBL26608256 0.74 LTA4H (0.49) MPOLTA4HMAPK14HTTSMN1; SMN2
SCHEMBL31488465 0.74 PLAU (0.45) LTA4HMAPK14HTTSMN1; SMN2STAT3
SCHEMBL4781292 0.73 HTT (0.54) MAPK14HTTSMN1; SMN2STAT3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 — — US disclosed
CN-119546580-A Heteroaryl compounds for the treatment of pain 沃泰克斯药物股份有限公司 2025-02-28 — — CN disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A MPO 1946/4885LTA4H 1063/4885MAPK14 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback